SCHEMBL4238366

SCHEMBL4238366

O=c1c2ccccc2nc(-c2ccco2)n1N(Cc1ccc(Br)cc1)Cc1ccc(Br)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASR P41180 1/20 0.56
ALDH1A1 P00352 9/20 0.56
SMN1; SMN2 Q16637 7/20 0.56
LMNA P02545 6/20 0.56
TSHR P16473 3/20 0.56
PKM P14618 1/20 0.56
MAPK1 P28482 3/20 0.50
USP2 O75604 2/20 0.49
TP53 P04637 1/20 0.49
ALOX15 P16050 1/20 0.49
HSD17B10 Q99714 1/20 0.49
HIF1A Q16665 1/20 0.49
HTT P42858 1/20 0.48
KDM4E B2RXH2 3/20 0.48
NPSR1 Q6W5P4 1/20 0.48
KMT2A Q03164 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
MEN1 O00255 1/20 0.47
CYP1A2 P05177 1/20 0.46
GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4237447 0.78 SMN1; SMN2 (0.56) CASRALDH1A1SMN1; SMN2LMNATSHR
SCHEMBL4240220 0.74 ALDH1A1 (0.51) CASRALDH1A1SMN1; SMN2LMNANPSR1
SCHEMBL31060812 0.72 CASR (1.00) CASRALDH1A1SMN1; SMN2LMNATSHR
SCHEMBL4246672 0.72 ALDH1A1 (0.49) CASRALDH1A1SMN1; SMN2LMNANPSR1
SCHEMBL4244091 0.71 ALDH1A1 (0.53) CASRALDH1A1SMN1; SMN2LMNANPSR1
SCHEMBL28773634 0.70 ALDH1A1 (0.62) CASRALDH1A1SMN1; SMN2LMNATSHR
SCHEMBL29737423 0.70 ALDH1A1 (0.62) CASRALDH1A1SMN1; SMN2LMNATSHR
SCHEMBL5800208 0.68 CASR (0.80) CASRALDH1A1SMN1; SMN2LMNATSHR
SCHEMBL4233146 0.66 KDM4E (0.52) ALDH1A1SMN1; SMN2LMNAPKMMAPK1
SCHEMBL5798662 0.64 SMN1; SMN2 (0.74) CASRALDH1A1SMN1; SMN2LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 GRK5, PLAAT5, GPBAR1 CASR 898/4885ALDH1A1 3192/4885SMN1; SMN2 4767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.